Compare Pfizer Inc (PFE) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Sezzle Inc — how do they compare? Pfizer Inc trades at $28.28 (market cap $158.56B), while Sezzle Inc trades at $128.64 (market cap $3.95B). The key difference: Pfizer Inc is far larger — about 40.1× Sezzle Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Sezzle Inc for 15 Days on average.
| PFE | SEZL | |
|---|---|---|
Market Cap | $158.56B | $3.95B |
Volume | 44,138,282 | 550,075 |
Sector | Health | Financials |
52-Week High | $29.02 | $188.55 |
52-Week Low | $23.67 | $50.97 |
Typical Hold Time | 158 Days | 15 Days |
Enterprise Value | $210.06B | $3.99B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
SEZL trades at $117.22, up 2.96% today, showing strong momentum with bullish technical indicators and trading above key support levels. The company demonstrates exceptional financial performance with 51.7% revenue growth in Q2 2026, 30.35% net income margin, and 88.85% ROE. Recent product launches including Sezzle Send and SezzleCash are driving user acquisition and platform growth.
SEZL presents a compelling growth opportunity with analyst consensus price target of $168 representing 43% upside potential. Key risks include competitive BNPL market pressures and potential credit quality concerns. The stock's premium valuation (P/E 25.71) is supported by strong earnings growth and profitability metrics, though investors should monitor execution of expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
